The EU Patent of the Best Selling Drug Has Expired, What Does it Mean for Biotech?
AbbVie’s Humira, a treatment for inflammatory disease and the world’s best-selling drug, is no longer…
October 17, 2018 - 2 minutes
Biosimilars
German Humira Biosimilar for Inflammatory Diseases Cleared for EMA Approval
Cyltezo, an adalimumab biosimilar drug by Boehringer Ingelheim, has received the backing to be marketed…
September 18, 2017 - 1 minute
Samsung Bioepis Gets European Approval for Biosimilar of Best-Selling Antibody
Samsung Bioepis has announced the European Commission approved Imraldi, a biosimilar of AbbVie's Humira (adalimumab),…
August 28, 2017 - 2 minutes
Biosimilars Struggle to Substitute Brand-Name Drugs
Despite bringing a significant price reduction, biosimilars might lag in taking over the market of…
August 16, 2017 - 2 minutes
Biosimilars set to take on Oncology after a new Market Authorization
The European Commission has approved Truxima, the world's first biosimilar monoclonal antibody (mAb) with an…
February 23, 2017 - 3 minutes
The FDA lays down Laws of Interchangeability: New Era for Biosimilars?
The new guidelines from the FDA on interchangeability may bring the US biosimilar market up…
February 8, 2017 - 4 minutes
Sanofi Jumps into the Biosimilars Market aiming for Asia
Sanofi is joining the biosimilars trend to challenge Roche's best-selling biological with a partnership that…
December 6, 2016 - 2 minutes
Boehringer’s Biosimilar could take a Chunk out of the Cancer Market
Boehringer Ingelheim is getting ready to launch a biosimilar for Roche's cancer blockbuster Avastin as…
November 17, 2016 - 2 minutes
What’s in the Cards for a Biosimilar after it Launches
As legal frameworks and regulatory pathways for biosimilars are in evolving all around the world,…
November 17, 2016 - 5 minutes
UPDATE: FDA rejects Sanofi’s promising Rheumatoid Arthritis Drug
Sanofi and Regeneron (NY, US) have ruled their phase III clinical trial immunotherapy Sarilumab a…
October 31, 2016 - 3 minutes
Boehringer enters the Biosimilar War against Blockbuster Humira
Boehringer Ingelheim just announced positive Phase III results for its Humira biosimilar. The company is…
October 27, 2016 - 2 minutes
Biosimilars are all the rage, but how do they compare to Generics?
Biosimilars could be the future of the pharmaceutical industry, as the market could grow 10-fold…
October 26, 2016 - 5 minutes
